S Waters
Cardiff University
9 Papers
4 Citations
S Waters is an academic researcher from Cardiff University. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 5, co-authored 9 publications.
Chat about Author
Papers
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Robert H. Jones,Angela C. Casbard,Margherita Carucci,Catrin Cox,Rachel Butler,Fouad S Alchami,Tracie-Ann Madden,Catherine Jane Bale,Pavel Bezecny,Johnathan Joffe,Sarah Moon,Chris Twelves,Ramachandran Venkitaraman,S Waters,Andrew Foxley,Sacha J Howell +15 more
TL;DR: The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.
196
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group
Hans Wildiers,Konstantinos Tryfonidis,Lissandra Dal Lago,Peter Vuylsteke,Giuseppe Curigliano,S Waters,Barbara Brouwers,Sevilay Altintas,Nathan Touati,Fatima Cardoso,Etienne Brain +10 more
TL;DR: This trial evaluated the efficacy of dual anti-HER2 treatment with or without metronomic chemotherapy in older patients with HER2-positive metastatic breast cancer in 30 centres from eight countries in Europe.
112
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.
Robert H. Jones,Margherita Carucci,Angela C. Casbard,Rachel Butler,Fouad S Alchami,Catherine Jane Bale,Pavel Bezecny,Johnathan Joffe,Sarah Moon,Chris Twelves,Ramachandran Venkitaraman,S Waters,Sacha J Howell +12 more
TL;DR: The PI3K/AKT signalling pathway is frequently activated in patients with estrogen receptor (ER) positive breast cancer (ER+BC) and has been implicated in endocrine therapy res...
37
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
Nicolò Matteo Luca Battisti,Belinda Kingston,Judy King,Arshi Denton,S Waters,Ailsa Sita-Lumsden,Farah Rehman,Chara Stavraka,Hartmut Kristeleit,Elinor J. Sawyer,David Houghton,Neville Davidson,Sacha J Howell,Julia Choy,Peter Harper,Rebecca Roylance,Raja Fharat,Kabir Mohammed,Alistair Ring,Stephen R. D. Johnston +19 more
TL;DR: This is the most extensive analysis of palbociclib in ≥ 4th-line setting and clinical benefit was confirmed particularly for endocrine-sensitive, predominantly bony disease and in earlier lines of treatment.
19
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
Cristina Saura,Cristina Saura,Judit Matito,Mafalda Oliveira,Hans Wildiers,Adam M. Brufksy,S Waters,Sara A. Hurvitz,Beverly Moy,Sung-Bae Kim,William J. Gradishar,Geraldo Silva Queiroz,Eduardo Cronemberger,Gerald J. Wallweber,Judith Bebchuk,Kiana Keyvanjah,Alshad S. Lalani,Richard A. Bryce,Ana Vivancos,Lisa D. Eli,Suzette Delaloge +20 more
TL;DR: In this article, the authors evaluated correlations between exploratory biomarkers and progression-free survival (PFS) in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 patients with HER2-positive (HER2+) metastatic breast cancer (MBC).